Skip to main content

Peer Review reports

From: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer

Original Submission
8 Jul 2023 Submitted Original manuscript
30 Jul 2023 Reviewed Reviewer Report - Dina M El-Habashy
28 Aug 2023 Reviewed Reviewer Report - Sanna Iivanainen
20 Oct 2023 Reviewed Reviewer Report
30 Nov 2023 Author responded Author comments - Ruoshuang Han
Resubmission - Version 2
30 Nov 2023 Submitted Manuscript version 2
27 Dec 2023 Author responded Author comments - Ruoshuang Han
Resubmission - Version 3
27 Dec 2023 Submitted Manuscript version 3
7 Jan 2024 Reviewed Reviewer Report - Dina M El-Habashy
24 Jan 2024 Reviewed Reviewer Report
30 Mar 2024 Author responded Author comments - Ruoshuang Han
Resubmission - Version 4
30 Mar 2024 Submitted Manuscript version 4
9 Apr 2024 Author responded Author comments - Ruoshuang Han
Resubmission - Version 5
9 Apr 2024 Submitted Manuscript version 5
Publishing
15 Apr 2024 Editorially accepted
24 Apr 2024 Article published 10.1186/s12916-024-03389-w

You can find further information about peer review here.

Back to article page